NK/T细胞淋巴瘤的治疗进展(英文)  

Novel therapy for NK/T cell lymphoma——Review

作　　者：徐笑笑[1] 张翼鷟[1] 

机构地区：[1]天津医科大学附属肿瘤医院血液科,天津300060

出　　处：《中国实验血液学杂志》2012年第6期1501-1506,共6页Journal of Experimental Hematology

基　　金：国家自然基金面上项目(30672208,81270603);天津市中青年骨干创新人才培养计划

摘　　要：NK/T细胞淋巴瘤是一种罕见的非霍奇金淋巴瘤,侵袭性高,预后差,临床上多将其分为鼻的,非鼻的和侵袭性淋巴瘤/白血病三种亚型。NK/T细胞淋巴瘤具有明显的地域差异,而且与EB病毒的感染密切相关。由于其发生率较低,临床预后不良,目前尚无明确的治疗策略。对于Ⅰ/Ⅱ期NK/T细胞淋巴瘤,联合化放疗具有较好的疗效;对于Ⅲ/Ⅳ期的患者,尤其是非鼻腔的及侵袭性的亚型,化疗是其主要的治疗方法;最近的研究结果证明,大剂量化疗联合自体或异体造血干细胞移植在部分病例中取得了令人瞩目的疗效。本文就NK/T细胞淋巴瘤的治疗进展进行综述。NK/T cell lymphoma, a rare type of non-Hodgkin＇s lymphoma, is a highly aggressive disease with poor prognosis. Clinically, it is classified into nasal, non-nasal, and aggressive lymphoma / leukemia subtypes. They are characterized by geographic distribution and are universally associated with Epstein-Barr virus （EBV） infection. Due to its low occurrence and dismal clinical outcome, no therapeutic strategy is currently identified in this disease. Combined chemotherapy and radiotherapy have better effects for stage I / U nasal NK cell lymphoma. As for stage III/IV nasal NK cell lymphoma and non-nasal, and aggressive subtypes, chemotherapy is the main treatment method. Recently, some studies have demonstrated promising outcomes in the selected cases by high-dose chemotherapy supplemented with auto- or allo-HSCT. In this article several treatment modalities adopted in recent years have been reviewed.

关 键 词：NK T细胞淋巴瘤 非霍奇金淋巴瘤 结外淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤] R979.1[医药卫生—临床医学]